Several brokerages have updated their recommendations and price targets on shares of InVitae Corp (NASDAQ: NVTA) in the last few weeks: 9/2/2015 – InVitae Corp was downgraded by analysts at Zacks from a “hold” rating to a “sell” rating. According to Zacks, “Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, […]
